 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...3334353637383940414243...100101» |
- || Ibrance (palbociclib) / Pfizer
Trial completion: Biological and Clinical Effects of Palbociclib With Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) - Apr 20, 2022
P2, N=24, Completed, Sponsor: NSABP Foundation Inc
Active, not recruiting --> Completed
- || lerociclib (G1T38) / Walvax, Pepper Bio
New P1 trial, Combination therapy, Metastases: A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer (clinicaltrials.gov) - Apr 20, 2022
P1, N=10, Recruiting, Sponsor: Genor Biopharma Co., Ltd.
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
Retrospective data, Review, Journal: Fertility preservation for women with breast cancer before chemotherapy: a systematic review and meta-analysis. (Pubmed Central) - Apr 19, 2022
A significantly lower peak serum estradiol level was observed in letrozole-based groups than in letrozole-free groups. In conclusion, our study indicated that implementing random-start protocols to shorten the duration of waiting for ovarian stimulation, applying two ovarian stimulation cycles, and coadministering letrozole can lead to more desirable outcomes.
- | letrozole / Generic mfg.
Journal: Butylated starch alleviates polycystic ovary syndrome by stimulating the secretion of peptide tyrosine-tyrosine and regulating faecal microbiota. (Pubmed Central) - Apr 19, 2022
Treatment with butylated starch (BS) alleviated abnormal ovarian morphology, metabolic disorders, and sex hormone imbalance in letrozole-treated rats, whereas treatment with acetylated starch and propylated starch did not exhibit such effects...In addition, compared with caecal microbiota, faecal microbiota was more affected by BS. Butyrate-producing microbes were enriched in faeces after BS treatment and may have helped further to relieve PCOS symptoms.
- | isoquercetin (IQC950AN) / Quercis Pharma
Journal: Chemical constituents from Carica papaya Linn. leaves as potential cytotoxic, EGFR and aromatase (CYP19A) inhibitors; a study supported by molecular docking. (Pubmed Central) - Apr 19, 2022
Moreover, methyl gallate and nicotiflorin exhibited potential EGFR kinase inhibition activities with an IC of 37.3 ± 1.9 and 41.08 ± 2.1 nM, respectively, compared with the positive control erlotinib (IC = 35.94 ± 1.8 nM)...Clitorin was comparable to the efficacy of the standard drug letrozole (IC = 77.72 ± 4.55)...Clitorin showed the strongest interaction with aromatase (CYP19A1) for the breast cancer receptor with a posing score of -14.2074 and RMSD value of 1.56 Å. Compounds (1-3) possessed a good bioavailability score with a 0.55 value.
- | letrozole / Generic mfg.
Journal: Evaluating the role of aromatase inhibitors in the treatment of low-grade endometrial stromal sarcomas. (Pubmed Central) - Apr 19, 2022
Our study suggests, however, that response rates may be lower than previously reported. Data on optimal duration of treatment is needed, but the rarity of LGESS is an obstacle to conducting large clinical trials.
- | Herceptin (trastuzumab) / Roche
Enrollment open, Trial primary completion date: ARETTA: Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer (clinicaltrials.gov) - Apr 18, 2022
P2, N=60, Recruiting, Sponsor: University of Chicago
Data on optimal duration of treatment is needed, but the rarity of LGESS is an obstacle to conducting large clinical trials. Active, not recruiting --> Recruiting | Trial primary completion date: Apr 2022 --> Sep 2022
- | Ibrance (palbociclib) / Pfizer
Retrospective data, Journal, Real-world evidence: The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer. (Pubmed Central) - Apr 15, 2022
We conclude that alternative dosing strategies used by oncologists such as prescribing palbociclib for three weeks on, two weeks off may achieve comparable disease control while mitigating neutropenic toxicities when compared to standard monograph dosing recommendations, prolonging treatment tolerability and adherence. Further large-scale studies are needed to confirm these results for future clinical adoption.
- | Ibrance (palbociclib) / Pfizer, letrozole / Generic mfg.
Please get Ibrance and Letrozole! (Twitter) - Apr 15, 2022
- ||| Kisqali (ribociclib) / Novartis
P3 data, Clinical Trial,Phase III, Journal: Ribociclib plus letrozole in male patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: subgroup analysis of the phase IIIb CompLEEment-1 trial. (Pubmed Central) - Apr 13, 2022
P3
The clinical benefit and overall response rates in males were consistent with the overall population. This analysis demonstrates the safety and efficacy of ribociclib in a close-to-real-world setting, supporting the use of RIB + LET in male patients with HR+, HER2- ABC.
- | tamoxifen / Generic mfg.
Journal: Acute pancreatitis secondary to tamoxifen-associated hypertriglyceridemia: A clinical update. (Pubmed Central) - Apr 13, 2022
It also underscores the importance of pre- and post-tamoxifen lipid screening, especially in patients with a history of dyslipidemia and diabetes mellitus. It will facilitate an expedient detection of hypertriglyceridemia, potentially saving patients from associated morbidity and mortality.
- | letrozole / Generic mfg., everolimus / Generic mfg.
Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Apr 13, 2022
P2, N=31, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
It will facilitate an expedient detection of hypertriglyceridemia, potentially saving patients from associated morbidity and mortality. Trial primary completion date: Apr 2021 --> Apr 2022
- | Piqray (alpelisib) / Novartis
Trial completion date: BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer (clinicaltrials.gov) - Apr 13, 2022
P1, N=46, Active, not recruiting, Sponsor: Vanderbilt-Ingram Cancer Center
Trial primary completion date: Apr 2021 --> Apr 2022 Trial completion date: Feb 2022 --> Aug 2022
- | metformin / Generic mfg., letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal: Assessment of Knowledge, Attitude, and Practice of Obstetricians and Gynecologists Toward Off-Label Medicine Use in Female Reproductive Health Issues. (Pubmed Central) - Apr 12, 2022
The present study revealed that the respondents were well-familiar with the practice of OLMU in the treatment of FRHIs. They expressed their concerns about decreasing such practices by being involved in collective decision-making procedures, and they were inclined to accept initiatives aimed at ensuring drug safety in patients.
- Ibrance (palbociclib) / Pfizer, Aliqopa (copanlisib) / Bayer
Trial completion date, Trial termination, Trial primary completion date: Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer (clinicaltrials.gov) - Apr 11, 2022
P2, N=10, Terminated, Sponsor: Jonsson Comprehensive Cancer Center
They expressed their concerns about decreasing such practices by being involved in collective decision-making procedures, and they were inclined to accept initiatives aimed at ensuring drug safety in patients. Trial completion date: Aug 2023 --> Mar 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Mar 2022; Insufficient accrual
- || Piqray (alpelisib) / Novartis
Trial completion date, Trial primary completion date, Metastases: METALLICA: Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients (clinicaltrials.gov) - Apr 11, 2022
P2, N=68, Recruiting, Sponsor: MedSIR
Trial completion date: Aug 2023 --> Mar 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2022 --> Mar 2022; Insufficient accrual Trial completion date: Dec 2022 --> Jul 2024 | Trial primary completion date: Jul 2021 --> Dec 2023
- | lapatinib / Generic mfg., letrozole / Generic mfg.
Journal: Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis. (Pubmed Central) - Apr 9, 2022
While neither agent influenced cell migration, glyceollin and lapatinib reduced S and G2/M phase cell entry and exclusively induced apoptosis by 1.29-fold in the T47DaromLR cells. Taken together, these results suggest that glyceollins and lapatinib may have potential as a novel combination therapeutic approach for hormone-dependent, letrozole-resistant tumors.
- || letrozole / Generic mfg.
Clinical protocol, Preclinical, Review, Journal: Live birth after letrozole as an adjunct to follicle-stimulating hormone versus follicle-stimulating hormone alone for ovarian stimulation in in vitro fertilisation cycles-study protocol for a randomised controlled trial. (Pubmed Central) - Apr 9, 2022
P3
Taken together, these results suggest that glyceollins and lapatinib may have potential as a novel combination therapeutic approach for hormone-dependent, letrozole-resistant tumors. The present study is the first multicentre randomised study to compare the live birth rate of the fresh embryo transfer following ovarian stimulation by letrozole and FSH versus FSH alone in women with anticipated high ovarian responses.
- ||| samotolisib (LY3023414) / Eli Lilly
Trial completion, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 8, 2022
P1, N=156, Completed, Sponsor: Eli Lilly and Company
The present study is the first multicentre randomised study to compare the live birth rate of the fresh embryo transfer following ovarian stimulation by letrozole and FSH versus FSH alone in women with anticipated high ovarian responses. Active, not recruiting --> Completed
- || Ibrance (palbociclib) / Pfizer
Biomarker, Clinical, Journal, PARP Biomarker: Biomarkers of response and resistance to palbociclib plus letrozole in patients with ER+/HER2- breast cancer. (Pubmed Central) - Apr 8, 2022
High CCNE1 levels were confirmed as a biomarker of resistance to letrozole+palbociclib. Ki67 recovery within 3-9 days of discontinuing palbociclib indicates incomplete suppression of proliferation during the "off" week of its schedule.
- | letrozole / Generic mfg., triptorelin / Generic mfg.
Journal: Clinical efficacy of dual trigger with human chorionic gonadotropin and a gonadotropin-releasing hormone agonist for women undergoing fertility preservation. (Pubmed Central) - Apr 8, 2022
The maturation rate was higher in the dual trigger group, although the difference was not statistically significant (59.3 ± 26.7 vs. 50.0 ± 28.0, p = 0.124). Dual triggering can be an efficient maturation method to maximize the yield of mature oocytes in breast or endometrial cancer patients using letrozole-combined GnRH antagonist protocol for FP.
- | letrozole / Generic mfg.
New P2/3 trial: GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients (clinicaltrials.gov) - Apr 6, 2022
P2/3, N=80, Not yet recruiting, Sponsor: Xiaojun Chen
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Review, Journal: Stimulation for low responder patients: adjuvants during stimulation. (Pubmed Central) - Apr 6, 2022
Although there currently is insufficient evidence to state categorically that it leads to an increased chance of a live birth. In the same situation, clomiphene citrate and letrozole lead to a reduced requirement for gonadotropins before oocyte retrieval, but with no improvement in live birth rate for their use.
- letrozole / Generic mfg., clomifene citrate / Generic mfg.
Intra-Ovarian Platelet Rich Plasma Administration and Improvement of Blastocyst Euploidy Rates in Women Undergoing IVF. () - Apr 6, 2022 - Abstract #SRI2022SRI_69;
The growth factors present in PRP may exhibit a local paracrine effect that could improve meiotic aberrations in human oocytes, thus improving euploidy rates. Whether PRP improves live birth rates and lowers miscarriage rates remains to be determined in large trials.Table 1: Euploidy rates before and after intraovarian PRP administrationPatientAgeCycle 1:# Euploid EmbryosCycle 1:# Aneuploid Embryos# Days between PRP and the start of Cycle 2Cycle 2:# Euploid EmbryosCycle 2:# Aneuploid EmbryosClinical outcome128014520CP233023810Pending ET339021501-43903, 1 mosaic6022Pending ET540131421CP641047831 mosaicCP7410122606-842033803-944106101-1044027501-1145017010Pending ET1245103301-
- | letrozole / Generic mfg.
Trial completion, Trial primary completion date: Follicular Synchronization in PCOS Patients Undergoing ICSI (clinicaltrials.gov) - Apr 6, 2022
P4, N=200, Completed, Sponsor: Mansoura University Hospital
Whether PRP improves live birth rates and lowers miscarriage rates remains to be determined in large trials.Table 1: Euploidy rates before and after intraovarian PRP administrationPatientAgeCycle 1:# Euploid EmbryosCycle 1:# Aneuploid Embryos# Days between PRP and the start of Cycle 2Cycle 2:# Euploid EmbryosCycle 2:# Aneuploid EmbryosClinical outcome128014520CP233023810Pending ET339021501-43903, 1 mosaic6022Pending ET540131421CP641047831 mosaicCP7410122606-842033803-944106101-1044027501-1145017010Pending ET1245103301- Recruiting --> Completed | Trial primary completion date: Aug 2021 --> Feb 2022
- || Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date: Roll-over Study to Allow Continued Access to Ribociclib (clinicaltrials.gov) - Apr 6, 2022
P4, N=137, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Aug 2021 --> Feb 2022 Trial completion date: Nov 2027 --> Feb 2028 | Trial primary completion date: Oct 2027 --> Jan 2028
- | letrozole / Generic mfg., alosetron / Generic mfg.
Preclinical, Journal: Estrogen and serotonin enhance stress-induced visceral hypersensitivity in female rats by up-regulating brain-derived neurotrophic factor in spinal cord. (Pubmed Central) - Apr 5, 2022
Trial completion date: Nov 2027 --> Feb 2028 | Trial primary completion date: Oct 2027 --> Jan 2028 Serotonin-mediated activation of 5HT3A receptors in the spinal cord drives the development of enhanced female-specific VHS in our two hit CPS+CAS through up-regulation of spinal cord ERα.
- | letrozole / Generic mfg., clomifene citrate / Generic mfg.
Journal, HEOR: Emulating a target trial of the comparative effectiveness of clomiphene citrate and letrozole for ovulation induction. (Pubmed Central) - Apr 5, 2022
The risks of adverse neonatal outcomes were slightly greater among women with PCOS who were treated with letrozole versus clomiphene. It is likely that these effects are partially mediated through an increased risk of multiple gestation among women who received letrozole.
- | letrozole / Generic mfg.
Preclinical, Journal: Reducing local synthesis of estrogen in the tubular striatum promotes attraction to same-sex odors in female mice. (Pubmed Central) - Apr 5, 2022
Letrozole's effects were not due to group differences in basal respiration, nor changes in the ability to detect or discriminate between odors (both monomolecular odorants and urinary odors). Therefore, de novo E2 synthesis in the TuS impacts females' but not males' attraction to female urinary odors, suggesting a sex-specific influence of E2 in odor hedonics.
- | tamoxifen / Generic mfg.
Retrospective data, Journal: Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. (Pubmed Central) - Apr 5, 2022
Using an aromatase inhibitor rather than tamoxifen in premenopausal women receiving ovarian suppression reduces the risk of breast cancer recurrence. Longer follow-up is needed to assess any impact on breast cancer mortality.
- | letrozole / Generic mfg.
Preclinical, Journal: Partially purified non-polar phytocomponents from Aloe barbadensis Mill. gel restores metabolic and reproductive comorbidities in letrozole-induced polycystic ovary syndrome rodent model- an "in-vivo" study. (Pubmed Central) - Apr 5, 2022
Longer follow-up is needed to assess any impact on breast cancer mortality. The above findings indicate the effectiveness of LP3, isolated from Aloe vera gel against letrozole induced PCOS in mice and may be used in the treatment of PCOS as an alternative to metformin.
- | Piqray (alpelisib) / Novartis
Journal: Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer. (Pubmed Central) - Apr 5, 2022
The above findings indicate the effectiveness of LP3, isolated from Aloe vera gel against letrozole induced PCOS in mice and may be used in the treatment of PCOS as an alternative to metformin. No abstract available
- || letrozole / Generic mfg.
Retrospective data, Review, Journal: Systematic review update and meta-analysis of randomized and non-randomized controlled trials of ovarian stimulation versus artificial cycle for endometrial preparation prior to frozen embryo transfer in women with polycystic ovary syndrome. (Pubmed Central) - Apr 5, 2022
Our study showed stimulated protocol is better than HRT regimen as an endometrial preparation for women with PCOS. However, quality of the evidence is low, more well-designed RCT studies are still needed to confirm the results before clinical recommendation, particularly direct comparisons between letrozole and other stimulated regimens.
- | minocycline / Generic mfg.
Preclinical, Journal: Molecular docking and mouse modeling suggest CMKLR1 and INSR as targets for improving PCOS phenotypes by minocycline. (Pubmed Central) - Apr 5, 2022
The mice were then divided into six groups (n=8 per group, mean body weight 17.77± 0.26): control (received normal saline), PCOS model, control for minocycline, minocycline treated PCOS (50 mg/kg), letrozole treated PCOS (0.5 mg/kg), and metformin-treated PCOS (300 mg/kg)...Minocycline may improve ovulation in PCOS model by returning E2 to a normal level and increasing CL number (ovulation signs). These beneficial outcomes may be related to the changes in CMKLR1 and INSR gene expression involved in glucose metabolism and inflammation.
- | metformin / Generic mfg., letrozole / Generic mfg.
Journal: The Effects of Letrozole and Metformin Combined with Targeted Nursing Care on Ovarian Function, LH, and FSH in Infertile Patients with Polycystic Ovary Syndrome. (Pubmed Central) - Apr 5, 2022
The combination of letrozole and metformin with targeted nursing in the treatment of infertility patients with PCOS has better clinical effect and high safety. It can improve endometrial receptivity and ovarian reserve function and regulate LH and FSH levels.
- | letrozole / Generic mfg.
Journal: Comparison of Perinatal Outcomes of Letrozole-Induced Ovulation and Hormone Replacement Therapy Protocols in Patients With Abnormal Ovulation Undergoing Frozen-Thawed Embryo Transfer: A Propensity Score Matching Analysis. (Pubmed Central) - Apr 5, 2022
For women with abnormal ovulation, the pregnancy and perinatal outcomes of HRT and L-OI protocols are reassuring. It seems that both protocols are safe and effective for endometrial preparation in frozen-thawed embryo transfer in the clinic.
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: A Trial of Personalized Acupuncture, Fixed Acupuncture, Letrozole and Placebo on Live Birth in Women With PCOS (clinicaltrials.gov) - Apr 5, 2022
P3, N=1100, Recruiting, Sponsor: Hongxia Ma
It seems that both protocols are safe and effective for endometrial preparation in frozen-thawed embryo transfer in the clinic. Trial completion date: Oct 2022 --> Jan 2024 | Trial primary completion date: May 2022 --> Oct 2023
- ||| atirmociclib (PF-07220060) / Pfizer, tagtociclib (PF-07104091) / Pfizer
Enrollment open, Combination therapy, Metastases: C4391002: A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors (clinicaltrials.gov) - Apr 4, 2022
P1b/2, N=144, Recruiting, Sponsor: Pfizer
Trial completion date: Oct 2022 --> Jan 2024 | Trial primary completion date: May 2022 --> Oct 2023 Not yet recruiting --> Recruiting
- | letrozole / Generic mfg., megestrol / Generic mfg.
Enrollment open: Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole in Young Women with Early Endometrial Cancer (clinicaltrials.gov) - Apr 4, 2022
P2, N=104, Recruiting, Sponsor: Fudan University
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer (clinicaltrials.gov) - Apr 4, 2022
P3, N=1050, Active, not recruiting, Sponsor: Borstkanker Onderzoek Groep
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Oct 2022 --> Jan 2023 | Trial primary completion date: Aug 2022 --> Jan 2023
- | fulvestrant / Generic mfg.
Journal: Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ER+ breast cancer. (Pubmed Central) - Apr 2, 2022
These data suggest nuclear FGFR1 contributes to endocrine resistance by modulating gene transcription in ER+ breast cancer. Nuclear FGFR1 activity was unaffected by FGFR TKIs, thus supporting the development of treatment strategies to inhibit nuclear FGFR1 in ER+/FGFR1 overexpressing breast cancer.
- ||| Trial completion date: MINDACT: Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes (clinicaltrials.gov) - Apr 1, 2022
P3, N=6600, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Nuclear FGFR1 activity was unaffected by FGFR TKIs, thus supporting the development of treatment strategies to inhibit nuclear FGFR1 in ER+/FGFR1 overexpressing breast cancer. Trial completion date: Jun 2022 --> Oct 2022
- | letrozole / Generic mfg.
Preclinical, Journal: Resveratrol Improves Follicular Development of PCOS Rats by Regulating the Glycolytic Pathway. (Pubmed Central) - Apr 1, 2022
Trial completion date: Jun 2022 --> Oct 2022 Resveratrol suppressed damage to the ovaries in PCOS rats by restoring glycolytic activity, providing potential targets for the treatment of PCOS.
- | tamoxifen / Generic mfg.
Journal: The regulatory effects of clomiphene and tamoxifen on mTOR and LC3-II expressions in relation to autophagy in experimental polycystic ovary syndrome (PCOS). (Pubmed Central) - Apr 1, 2022
In conclusion, present study suggests that TMX and CC induce autophagy in ovaries with PCOS. Autophagy is a promising target for understanding pathophysiology of this disease and for developing more effective and safe new protocols for the treatment of PCOS-related anovulation.
- || Norprolac (quinagolide) / Ferring
Clinical, Retrospective data, Review: Comparison of the Effectiveness of Various Medicines in the Prevention of Ovarian Hyperstimulation Syndrome: A Network Meta-Analysis of Randomized Controlled Trials. (Pubmed Central) - Apr 1, 2022
These drugs were safe and did not affect clinical pregnancy, miscarriage, or live birth rates. Calcium, HES, and cabergoline could effectively and safely prevent moderate-to-severe OHSS, with calcium as the most effective intervention.
- | letrozole / Generic mfg.
Journal: Does adjuvant letrozole reduce uterine peristalsis prior to fresh embryo transfer? (Pubmed Central) - Apr 1, 2022
P2/3
Modulating the luteal phase sex steroids with adjuvant letrozole had little measured impact on UPF. Any beneficial effect of adjuvant letrozole during ovarian stimulation is unlikely to be due to significant modulation of UPF.
- | letrozole / Generic mfg.
New P4 trial: Randomized Placebo-Controlled Clinical Trials on the Effect of Letrozole on Recovery from Non-Prescribed Androgen Use (EUDRACT) - Apr 1, 2022
P4, N=45, Not yet recruiting, Sponsor: NHMRC
- ||| LOXO-783 / Eli Lilly
New P1 trial, Combination therapy, Monotherapy, Metastases: PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) - Apr 1, 2022
P1, N=260, Not yet recruiting, Sponsor: Eli Lilly and Company
- | letrozole / Generic mfg.
Trial completion date, Trial primary completion date: Letrozole in Stimulated IVF Cycles (clinicaltrials.gov) - Mar 31, 2022
P3, N=900, Recruiting, Sponsor: The University of Hong Kong
Any beneficial effect of adjuvant letrozole during ovarian stimulation is unlikely to be due to significant modulation of UPF. Trial completion date: Dec 2022 --> Oct 2023 | Trial primary completion date: Dec 2021 --> Apr 2022
- | anastrozole / Generic mfg.
Journal, IO biomarker: Anastrozole regulates fatty acid synthase in breast cancer. (Pubmed Central) - Mar 31, 2022
Repressing FASN causes regression of breast cancer cell growth. The anastrozole-FASN signaling pathway is eminently targetable in endocrine-resistant breast cancer.